Stem cells can cure spinal cord injury
What Patients SayI watched a documentary about a man who was paralysed and walked again after stem cell injections. If stem cells can do that, why isn't it available everywhere? The doctors must be holding something back.
Where Did This Come From?
I want to begin this chapter differently from the others, because the person reading it may be someone living with paralysis, or someone who loves them. The emotional weight of this subject is not something I am going to glide past.
If you are in that position — if you or someone close to you has a spinal cord injury — I want to be genuinely honest with you rather than either dismissive or falsely optimistic. Because you deserve the truth, not a comfortable story.
The truth is this: spinal cord injury research is more active, more serious, and more scientifically grounded than it has ever been. The CELLTOP trial at Mayo Clinic — a Phase 1 study using patients' own fat-derived mesenchymal stem cells, injected intrathecally — reported that 7 of 10 participants improved by at least one ASIA impairment grade at final follow-up. No serious adverse events were attributed to the cell therapy. This is genuinely meaningful early-phase evidence. The Phase 2 trial is now enrolling.
And also: this was a 10-person Phase 1 safety trial. Most improvements were modest — increased sensation to light touch and pinprick, increased strength in specific muscle groups. One participant was a dramatic responder who recovered substantially. Most were not. Phase 1 trials are designed to establish safety and signal, not to establish efficacy. The headline "7 of 10 got better" requires the context that "better" ranged from modest to substantial, that Phase 1 results frequently do not replicate at scale, and that CELLTOP Phase 2 exists precisely because we do not yet know whether this works reliably enough to become a treatment.
What patients also need to understand: the ASIA grade system measures neurological status, and a one-grade improvement — while genuinely meaningful for quality of life — does not necessarily mean walking. It may mean recovering sensation in a specific dermatome, or recovering partial motor function in a muscle group. These improvements matter enormously. They are not the "walking again" headline most patients imagine.
The structural challenge in spinal cord injury regeneration is profound. After injury, there is immediate cell death (primary injury), followed by a cascade of secondary injury — inflammation, oedema, excitotoxicity, apoptosis, and eventually scar formation (the glial-fibrotic barrier). This scar serves a protective function but also physically and chemically blocks regenerating axons. Lost cells cannot simply be replaced by new ones and immediately establish functional connections — the nervous system requires those connections to be formed, reinforced, and integrated. Stem cells injected into the injured cord face all of these barriers. The few that survive likely exert their effects through trophic and immunomodulatory mechanisms — supporting surviving cells, dampening inflammation — rather than directly replacing lost neurons.
Clinics offering stem cell treatments for chronic complete spinal cord injury, outside of registered trials, are not offering this nuanced picture. They are offering hope. And charging for it.
The Verdict
As a routine clinical treatment. Legitimate research is active, scientifically serious, and showing early signals worth pursuing through proper trials. Commercial stem cell tourism for SCI is not the same thing and carries real risks without established benefit.
What To Do Instead
- Connect with the Christopher and Dana Reeve Foundation and Unite 2 Fight Paralysis — both maintain updated, patient-accessible registries of legitimate SCI research trials
- Ask any clinic offering stem cell treatment for SCI for their published trial data, IND number, and ASIA grade outcome distribution — not testimonials, data
- Understand the distinction between incomplete and complete SCI (see Beyond the Myth below) — this is the single most important predictor of recovery potential
- Invest in evidence-based rehabilitation — even where neurological recovery is limited, rehabilitation demonstrably improves independence, reduces complications, and improves quality of life
Yellow Flags — Worth Monitoring
- Media coverage of single dramatic cases — always check whether the patient had a complete or incomplete injury, and whether spontaneous recovery and rehabilitation effects were controlled for
- Clinics combining SCI stem cell treatment with general wellness offerings — serious SCI research is done by specialist neurology and rehabilitation centres, not wellness platforms
Red Flags — Seek Independent Advice
- Any provider guaranteeing functional recovery from a clinically complete (ASIA A) spinal cord injury — this is not something current science supports, in a trial or outside one
- Intrathecal injections of uncharacterised biological products offered outside of a registered trial — this is a high-risk procedure that requires expert oversight and emergency backup
- Bydon M et al., "CELLTOP Clinical Trial: First Report From a Phase 1 Trial of Autologous Adipose-Derived Mesenchymal Stem Cells in the Treatment of Paralysis Due to Traumatic Spinal Cord Injury," Mayo Clinic Proceedings, 2020. Full Phase 1 results: 7/10 participants improved ≥1 AIS grade; no serious adverse events attributable to cell therapy. Phase 2 (CELLTOP 2) enrolling as of 2024–2025.
- U.S. Food and Drug Administration. "Important Patient and Consumer Information About Regenerative Medicine Therapies." FDA.gov, 2024.